Claritev account plan
Healthcare pricing transparency solutions
At a glance
Claritev (formerly MultiPlan) is a US healthcare technology and data company that prices claims for over 750 payers; FY2025 revenues $965.4 million.
Claritev, formerly MultiPlan, is a US healthcare technology, data and insights company founded in 1980 that helps payers cut medical costs, mostly by repricing out-of-network claims before they are paid. It works directly with over 750 payers (ASO platforms, TPAs, carriers) and its clients served over 100,000 self-insured employers and plan sponsors in 2025; substantially all revenue is in the United States. FY2025 revenues were $965.4 million (+3.7%), Adjusted EBITDA $602.6 million and net loss $284.3 million, with approximately 3,000 full-time employees at December 31, 2025. It is listed on the NYSE (CTEV); H&F and the Sponsor own a significant equity interest.
Business units
Claims Intelligence Solutions
$639.9 million FY2025 revenue, about 66% of revenueAlgorithms that detect out-of-network claims priced above fair market value and negotiate or recommend a fair reimbursement before payment, including Reference-Based Pricing (Data iSight), Negotiation Services, Surprise Bill Services for the No Surprises Act and Vistara. It grew 17.1% to $192.5 million in Q3 2026, driven by Data iSight and Surprise Bill Services.
Network Solutions
$206.7 million FY2025 revenue, about 21% of revenueContracted discounts with more than 1.4 million providers, including the national PHCS Network, complementary, government and property and casualty networks, and outsourced network management. FY2025 growth of 11.6% included $18.0 million of one-time property and casualty revenue; Q3 2026 revenue fell 5.6% to $49.9 million against that non-recurring base.
Payment and Revenue Integrity Solutions
$118.9 million FY2025 revenue, about 12% of revenueIdentifies improper charges before or after payment (clinical negotiation, coordination of benefits, subrogation, data mining) and restores premium dollars underpaid to Medicare Advantage plans. Q3 2026 revenue fell 9.8% to $25.9 million on lower Clinical Negotiation; management expects a return to growth in 2027.
Data and Analytics Solutions
Descriptive, predictive and prescriptive analytics sold on subscription or licensing terms to employers, brokers, TPAs and carriers, including PlanOptix, CompleteVue and BenInsights. Its revenue is reported inside Claims Intelligence; the company estimates a TAM of $17.0 billion for new markets such as payer risk analytics and network transparency.
Strategic priorities
- Vision 2030 growth strategy
- Created in 2024, Vision 2030 sells horizontal solutions into vertical markets (payers, TPAs, employers, providers, government, international). 2025 was branded "THE TURN" and 2026 "THE WAY UP"; $45.0 million of transformation costs were incurred in 2025.
- Diversification beyond payers
- In Q3 2026, 26% of year-to-date bookings came from TPAs and 25% from newer markets (provider, public sector, international); pipeline is up about 60% year over year, with less than half from payers. TPAs were expected to bring roughly 30% of 2026 new bookings.
- Bookings growth
- More than $100 million of ACV was booked year to date by Q3 2026 against $67 million for all of 2025; full-year ACV bookings are expected at $115-125 million (70% to 90% growth).
- AI across workflows
- Dozens of AI agents are in production, the Chief Digital Officer's team has four dozen AI scientists, and 53% of code was delivered with AI in Q1 2026, with 60% to 80% targeted by year end. AI is aimed first at NSA disputes, then manual intake, claims processing and sales lead targeting.
- Free cash flow and deleveraging
- Returning to positive free cash flow is management's "number one financial priority"; Q4 2026 free cash flow is expected at $74-84 million, and net leverage was 7.7 times in Q3 2026. The long-term aim is "a Rule of 70 company".
Latest results
In Q3 2026 (quarter ended September 30, 2026) revenues were $268.3 million, up 9.1% from $246.0 million, the sixth consecutive quarter of year-over-year growth; nine-month revenues were $770.5 million (+7.2%). Claims Intelligence grew 17.1% while Network fell 5.6% and Payment and Revenue Integrity fell 9.8%. Net loss narrowed to $61.8 million (from $69.8 million) and Adjusted EBITDA was $162.0 million, with margin down to 60.4% from 63.1%. Free Cash Flow was $(25.8) million and unrestricted cash $10.1 million at quarter end. FY2026 guidance was raised to revenues of $1.038-1.043 billion, Adjusted EBITDA of $625-630 million and Free Cash Flow of $10-20 million, with preliminary 2027 revenue expectations of $1.1 billion.
Investments and deals
- January 2025 refinancing
- New First Lien Term Loans ($325.0 million first-out and $1,143.9 million second-out, maturing December 31, 2030) and a $350.0 million revolver maturing December 31, 2029; long-term debt was $4,560.4 million at December 31, 2025.
- Technology transformation capex
- FY2026 capex guidance is $165-170 million; nine-month 2026 investing outflow rose to $128.8 million on investment in technologies for the transformation. Most applications have moved to the cloud on a new data architecture, and a new ERP system was implemented.
- OPCG asset acquisition
- On November 10, 2025 Claritev acquired OPCG, LLC assets for $4.8 million in cash, adding healthcare program management and consulting expertise.
- MENA expansion
- In 2025 Claritev made its first international expansion, into the MENA region, through a partnership with Claims Care, a division of Burjeel Holdings.
- Go-to-market investment
- $20 to $25 million of planned 2026 investment in sales, marketing, go-to-market and delivery, alongside a five-year share repurchase program of up to $75.0 million (2026-2030).
Challenges and risks
- Client concentration
- Two clients were 29.2% and 10.4% of FY2025 revenues, and one client accounted for 38.0% of Q3 2026 revenue.
- Heavy leverage and thin liquidity
- Long-term debt was $4,560.4 million at end-2025 with $392.0 million of interest expense; at Q3 2026 cash and cash equivalents were $10.1 million and $95.0 million was drawn on the $350.0 million revolver.
- Antitrust litigation
- Antitrust class actions alleging suppression of out-of-network reimbursements are centralized in the Northern District of Illinois with discovery ongoing; the DOJ issued a civil investigative demand on May 19, 2026. Antitrust legal expenses were $21.5 million for the first nine months of 2026.
- IT control material weaknesses
- Material weaknesses in IT general controls (program change management and user access) found at December 31, 2025 remained unremediated at September 30, 2026; remediation is expected in fiscal 2026.
- Payment and Revenue Integrity behind plan
- PRI revenue fell 9.8% in Q3 2026 as clinical negotiations moved into Claims Intelligence; only about 20% of more than $40 million of PRI ACV booked over four quarters had converted to revenue.
What leadership says
“Claritev is a growth company, period.”
“We are not a widget or a point solution looking for an exit or a home.”
“running approximately a year ahead of our March 2026 Investor Day plan, with preliminary 2027 revenue expectations of $1.1 billion”
“No company has demonstrated a greater ability to manage NSA claims at scale than Claritev.”
Where a supplier can help
- AI and automation tooling
- Tied to the AI-across-workflows priority: with dozens of agents in production and a target of 60% to 80% of code delivered with AI, suppliers of AI development, model operations and claims-intake automation have a stated buyer.
- IT controls and security remediation
- Tied to the unremediated IT general control material weaknesses: providers of access management, change management and audit-readiness tooling or services fit a remediation due in fiscal 2026.
- Go-to-market for new verticals
- Tied to the diversification priority and the $20 to $25 million of 2026 go-to-market investment: sales enablement, partner channel and market-data suppliers can support selling into TPAs, providers, public sector and international markets.
- Cloud cost and hosting efficiency
- Tied to the free cash flow priority and rising software hosting costs in G&A: cloud cost optimisation and infrastructure efficiency offerings align with management's push to improve free cash flow conversion.
- Legal and dispute operations
- Tied to the antitrust litigation challenge and the NSA dispute volumes: e-discovery, legal operations and dispute-processing services address costs the documents name.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Claritev?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Claritev Corporation Annual Report on Form 10-K for fiscal year 2025
- Claritev (formerly MultiPlan; operating subsidiary Multiplan, Inc., d/b/a Claritev) is a US healthcare technology, data and insights company founded in 1980 that helps payers cut medical costs, mostly by pricing out-of-network claims before payment; it serves more than 750 payers and over 100,000 employers/plan sponsors, with over 60 million consumers having access to its solutions.
- FY2025 revenues were $965.4 million (+3.7% vs $930.6 million in 2024), a return to growth; Adjusted EBITDA was $602.6 million; net loss $284.3 million (vs $1,645.8 million in 2024, which included a $1,488.9 million goodwill and intangible impairment).
- Four solution categories: Claims Intelligence ($639.9 million revenue, +0.8%), Network ($206.7 million, +11.6%, helped by $18.0 million one-time property and casualty revenue), Payment and Revenue Integrity ($118.9 million, +7.5%); Data and Analytics is reported inside Claims Intelligence. Managed as a single segment.
- High client concentration: two clients were 29.2% and 10.4% of 2025 revenues; over 84.5% of 2025 revenues are attributed to self-insured plans.
- Strategy is "Vision 2030" (created in 2024): horizontal solutions sold into vertical markets (payers, TPAs, employers, providers, government, international), with 2025 branded "THE TURN" and 2026 "THE WAY UP"; $45.0 million of transformation costs in 2025.
- Heavy leverage: long-term debt of $4,560.4 million at end-2025 after the January 30, 2025 refinancing (maturities pushed to 2029-2031); interest expense $392.0 million; cash $28.3 million and $323.6 million available on the $350.0 million revolver.
- Scale: $25.0 billion potential savings identified on $179.8 billion claim charges in 2025; about 30 million claims processed every month; over 1.4 million contracted providers; approximately 3,000 full-time employees.
- Key risks: client concentration, antitrust class actions centralized in the Northern District of Illinois (discovery ongoing; $16.9 million antitrust legal costs in 2025), provider pushback on cost management, indebtedness, and material weaknesses in IT general controls.
- First international expansion in 2025 into the MENA region through a partnership with Claims Care (a division of Burjeel Holdings); small OPCG asset acquisition for $4.8 million in November 2025.
- Claritev Corporation Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)
- Q3 2026 revenues were $268.3 million, up 9.1% from $246.0 million in Q3 2025; nine-month revenues were $770.5 million, up 7.2%.
- Claims Intelligence drove all the growth: $192.5 million in Q3 (+17.1%), from Data iSight and Surprise Bill Services; Network fell 5.6% to $49.9 million (non-recurring property and casualty revenue in the prior year) and Payment and Revenue Integrity fell 9.8% to $25.9 million (lower Clinical Negotiation).
- Q3 net loss narrowed to $61.8 million (from $69.8 million); Adjusted EBITDA $162.0 million (vs $155.1 million); Adjusted EPS $1.77 (vs $1.48).
- G&A rose to $66.3 million, driven by $15.2 million higher other G&A for antitrust legal expenses and software hosting; transformation costs fell to $8.0 million.
- One client accounted for 38.0% of Q3 revenue (two clients were 29.2% and 10.4% in FY2025).
- Liquidity is thin: $10.1 million of cash and cash equivalents, $95.0 million drawn on the $350.0 million revolver; nine-month investing outflow rose to $128.8 million on transformation technology investment.
- The DOJ closed its antitrust grand jury proceeding without criminal action (confirmed July 6, 2026), but issued a civil investigative demand on May 19, 2026; IT-control material weaknesses remain unremediated.
- Claritev Corporation Reports Third Quarter 2026 Results (press release)
- Q3 2026 revenues of $268.3 million grew 9.1%; net loss $61.8 million; Adjusted EBITDA $162.0 million (+4.4%), with margin down to 60.4% from 63.1%.
- Free Cash Flow was $(25.8) million in Q3 (vs $(16.3) million); operating cash flow $18.1 million; $10.1 million unrestricted cash at quarter end.
- FY2026 guidance raised for revenues to $1.038-1.043 billion (from $1-1.02 billion), Adjusted EBITDA to $625-630 million (from $610-620 million) and Free Cash Flow to $10-20 million; capex $165-170 million.
- CFO Doug Garis: running about a year ahead of the March 2026 Investor Day plan, with preliminary 2027 revenue expectations of $1.1 billion.
- CEO Travis Dalton: "dozens of AI agents already at work inside our workflows"; Client Conference showcased Transparency-Based Pricing, the Healthcare Intelligence platform and expanded Medicare Advantage offerings.
- Claritev serves more than 750 payers, over 100,000 employers, 60 million consumers and 1.4 million contracted providers.
- Claritev Q3 2026 earnings call transcript
- CEO Travis Dalton: "Claritev is a growth company, period"; the company is a full year ahead of its March 2026 Investor Day plan and now expects at least $1.1 billion revenue in 2027 (the Investor Day had it for 2028).
- Bookings: $27 million ACV in Q3, more than $100 million year to date vs $67 million for all of 2025; full-year ACV bookings now expected at $115-125 million (70% to 90% growth). 78% of year-to-date bookings came from existing clients; 26% from TPAs and 25% from newer markets (provider, public sector, international).
- Five new logos in Q3, 46 net new clients over two years; pipeline up about 60% year over year, less than half from payers.
- NSA (No Surprises Act) work is the growth engine: dispute initiations up 75% year over year; Claims Intelligence grew 17.1%, mostly from an early-2026 client win; Claritev claims 8% better performance than the industry average.
- New products shown at the Nashville Client Conference (100+ clients): a Medicare Advantage offering bundling more than 15 solutions, Transparency-Based Pricing built on public MRF data, and Claritev Healthcare Intelligence with an AI agent called Clara.
- AI: dozens of agents in production, four dozen AI scientists, 53% of code delivered with AI in Q1, aiming for 60% to 80% by year end.
- Payment and Revenue Integrity is behind plan (clinical negotiations moving into Claims Intelligence) but expected to return to growth in 2027; over $40 million of PRI ACV booked over four quarters.
- Q4 expected to be the strongest free cash flow quarter in more than four years ($74-84 million); net leverage 7.7x; long-term aim of a Rule of 70 company.
- Claritev Q2 2026 earnings call transcript
- Q2 2026 revenue $257.5 million, up 6.6% year over year (nearly 9% excluding last year's one-time revenue), the highest quarter in 15 quarters; Adjusted EBITDA $155.8 million (60.5% of revenue).
- Bookings: $30 million ACV in Q2, more than $70 million in H1 (H1 bookings up 150%), already above the $67 million of all 2025; $100 million full-year bookings target; over $300 million active pipeline.
- TPA vertical was the largest Q2 bookings contributor (several seven-figure deals, including Marpai for prepay and post-pay payment integrity), led by new segment leader Dale White; TPAs expected to bring roughly 30% of 2026 new bookings.
- NSA (No Surprises Act): arbitration outcomes about eight percentage points better than the industry; nearly half of IDR submissions are ineligible, an AI opportunity; surprise bill is now the second largest offering.
- AI and digital transformation: most applications moved to cloud; more than half of code generated by AI; expects "approximately the same number of humans doing four to eight times more work" across over 400 applications.
- Guidance raised: revenue $1 billion to $1.02 billion (4% to 6% growth), Adjusted EBITDA $610-620 million, free cash flow $5-15 million.
- Payer is about 80% of revenue and TPA a little less than 20%; Everest Group named Claritev a leader in payment integrity.
Questions about Claritev
What does Claritev do?
Claritev is a US healthcare technology, data and insights company that helps payers cut medical costs, mainly by pricing out-of-network claims before payment. It also runs one of the largest US provider networks, payment integrity services and data analytics products.
What is Claritev's revenue?
FY2025 revenues were $965.4 million, up 3.7%. For FY2026 the company guides to revenues of $1.038-1.043 billion and expects at least $1.1 billion in 2027.
How many employees does Claritev have?
Claritev had approximately 3,000 full-time employees at December 31, 2025.
What is Claritev's strategy?
Vision 2030 sells horizontal solutions into vertical markets such as payers, TPAs, employers, providers, government and international, backed by AI investment. 2026 is branded "THE WAY UP", with priorities of growth in the core, diversification, free cash flow and delevering.
Who leads Claritev?
Travis S. Dalton is President, CEO and Executive Chair, and Douglas M. Garis is EVP and CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)